20/20 Biolabs Inc (AIDX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 8, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AIDX SEC filings page.
20/20 Biolabs Inc (AIDX) reported $2.0M in revenue for fiscal year 2025, up 16.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue growth and gross-margin expansion narrowed losses, but liability growth erased equity and tightened near-term liquidity.
Gross-margin expansion from20.6% to29.6% coincided with lower SG&A and R&D spending, showing that the improved operating result came from both better gross economics and reduced overhead. However, operating cash flow improved only from-$2.6M to-$1.9M , so the accounting improvement has not yet become internally generated cash.
Balance-sheet deterioration accompanied the narrower loss: liabilities rose from
The current ratio dropped from 1.5x to 0.6x, indicating that short-term obligations grew faster than current assets. Liquidity equaled 6.4 months of reported annual operating outflow, while FY2025 financing cash inflow was
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of 20/20 Biolabs Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
20/20 Biolabs Inc's reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 21/100.
20/20 Biolabs Inc's revenue surged 16.7% year-over-year to $2.0M, reflecting rapid business expansion. This strong growth earns a score of 78/100.
20/20 Biolabs Inc's current ratio of 0.60 is below the typical benchmark, resulting in a score of 6/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Not available for 20/20 Biolabs Inc, and counted as zero in the overall score.
20/20 Biolabs Inc scores -12.64, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($7.4M) relative to total liabilities ($4.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
20/20 Biolabs Inc passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
20/20 Biolabs Inc reported a net loss of $3.7M while operations used $1.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
20/20 Biolabs Inc reported an operating loss of $3.3M against $156K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
20/20 Biolabs Inc generated $731K in revenue in Q2 2026. This represents an increase of 36.5% from the same quarter a year earlier. Against the prior quarter it is up 106.7%.
20/20 Biolabs Inc's EBITDA was -$1.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 48.4% from the same quarter a year earlier. Against the prior quarter it is up 14.4%.
20/20 Biolabs Inc reported -$1.5M in net income in Q2 2026. This represents a decrease of 79.1% from the same quarter a year earlier. Against the prior quarter it is up 30.7%.
20/20 Biolabs Inc earned -$0.26 per diluted share (EPS) in Q2 2026. This represents a decrease of 52.9% from the same quarter a year earlier. Against the prior quarter it is up 7.1%.
Cash & Balance Sheet
20/20 Biolabs Inc held $4.5M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
20/20 Biolabs Inc's gross margin was 41.7% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 11.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 23.9 percentage points.
20/20 Biolabs Inc's ROE was -92.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 146.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 7.8 percentage points.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
20/20 Biolabs Inc invested $258K in research and development in Q2 2026. This represents an increase of 32.7% from the same quarter a year earlier. Against the prior quarter it is up 67.9%.
Not reported for Q2 2026.
Not reported for Q2 2026.
AIDX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'24S-1 |
|---|---|---|---|---|---|---|
| Revenue | $731K+36.5% | $353K-36.2% | N/A | $535K | $554K | N/A |
| Cost of Revenue | $426K+14.5% | $290K-25.1% | N/A | $372K | $388K | N/A |
| Gross Profit | $305K+86.6% | $63K-62.1% | N/A | $163K | $166K | N/A |
| R&D Expenses | $258K+32.7% | $153K+12.2% | N/A | $194K | $137K | N/A |
| SG&A Expenses | $1.3M+58.5% | $1.4M+68.9% | N/A | $815K | $801K | N/A |
| Operating Income | -$1.2M-47.1% | -$1.4M-86.9% | N/A | -$846K | -$772K | N/A |
| EBITDA | -$1.2M-48.4% | -$1.4M-89.7% | N/A | -$825K | -$754K | N/A |
| Interest Expense | $272K+29017.1% | $267K+35982.2% | N/A | $935 | $740 | N/A |
| Net Income | -$1.5M-79.1% | -$2.2M-184.4% | N/A | -$841K | -$765K | N/A |
| EPS (Basic) | -$0.26-52.9% | -$0.28-75.0% | N/A | -$0.17 | -$0.16 | N/A |
| EPS (Diluted) | -$0.26-52.9% | -$0.28 | N/A | -$0.17 | -$0.16 | N/A |
| Diluted Shares (Avg) | 11M+123.7% | 8M | N/A | 5M | 5M | N/A |
Not reported in any period shown, so not listed: Income Tax.
AIDX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'24S-1 |
|---|---|---|---|---|---|---|
| Total Assets | $6.1M | $5.8M | $4.1M+15.4% | N/A | N/A | $3.6M |
| Current Assets | $5.1M | $4.7M | $1.5M-27.7% | N/A | N/A | $2.0M |
| Cash & Equivalents | $4.5M+344.0% | $4.2M+170.8% | $1.0M-42.5% | $1.0M | $1.6M | $1.8M |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $111K | $105K | $116K+146.4% | N/A | N/A | $47K |
| Accounts Receivable | $291K | $201K | $200K+47.8% | N/A | N/A | $135K |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $4.5M | $3.0M | $4.2M+99.9% | N/A | N/A | $2.1M |
| Current Liabilities | $2.6M | $2.6M | $2.5M+81.8% | N/A | N/A | $1.4M |
| Non-Current Liabilities | $413K | $466K | $1.7M+133.9% | N/A | N/A | $724K |
| Total Equity | $1.6M+360.9% | $2.6M+140.2% | -$19K-101.3% | $352K | $1.1M | $1.5M |
| Retained Earnings | -$36.9M | -$35.4M | -$33.2M-12.7% | N/A | N/A | -$29.5M |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
AIDX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'24S-1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$605K-13.4% | -$1.3M-164.0% | N/A | -$534K | -$488K | N/A |
| Depreciation & Amortization | $19K-6.4% | $12K-31.0% | N/A | $20K | $18K | N/A |
| Stock-Based Compensation | N/A | $128K-0.9% | N/A | N/A | $130K | N/A |
| Investing Cash Flow | -$8K | -$5K | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $940K | $4.5M+1610.6% | N/A | $0 | $262K | N/A |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
AIDX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'24S-1 |
|---|---|---|---|---|---|---|
| Gross Margin | 41.7%+11.2pp | 17.8%-12.1pp | N/A | 30.5% | 29.9% | N/A |
| Operating Margin | -170.3% | -408.5% | N/A | -158.1% | -139.4% | N/A |
| Net Margin | -206.2% | -615.4% | N/A | -157.2% | -138.1% | N/A |
| Return on Equity | -92.9%+146.2pp | -85.2%-13.3pp | N/A | -239.2% | -71.9% | N/A |
| Return on Assets | -24.6% | -37.5% | N/A | N/A | N/A | N/A |
| Current Ratio | 1.99 | 1.82 | 0.60-0.9x | N/A | N/A | 1.50 |
| Debt-to-Equity | 2.78 | 1.19 | N/A | N/A | N/A | 1.38 |
| Asset Turnover | 0.12 | 0.06 | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$19K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.60), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Where 20/20 Biolabs Inc Ranks
Frequently Asked Questions
What is 20/20 Biolabs Inc's annual revenue?
20/20 Biolabs Inc (AIDX) reported $2.0M in total revenue for fiscal year 2025. This represents a 16.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is 20/20 Biolabs Inc's revenue growing?
20/20 Biolabs Inc (AIDX) revenue grew by 16.7% year-over-year, from $1.8M to $2.0M in fiscal year 2025.
Is 20/20 Biolabs Inc profitable?
No, 20/20 Biolabs Inc (AIDX) reported a net income of -$3.7M in fiscal year 2025.
What is 20/20 Biolabs Inc's EBITDA?
20/20 Biolabs Inc (AIDX) had EBITDA of -$3.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is 20/20 Biolabs Inc's gross margin?
20/20 Biolabs Inc (AIDX) had a gross margin of 29.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is 20/20 Biolabs Inc's operating cash flow?
20/20 Biolabs Inc (AIDX) recorded an outflow of $1.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are 20/20 Biolabs Inc's total assets?
20/20 Biolabs Inc (AIDX) had $4.1M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does 20/20 Biolabs Inc spend on research and development?
20/20 Biolabs Inc (AIDX) invested $593K in research and development during fiscal year 2025.
What is 20/20 Biolabs Inc's current ratio?
20/20 Biolabs Inc (AIDX) had a current ratio of 0.60 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is 20/20 Biolabs Inc's return on assets (ROA)?
20/20 Biolabs Inc (AIDX) had a return on assets of -90.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is 20/20 Biolabs Inc's P/E ratio?
20/20 Biolabs Inc (AIDX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $7.4M as of Sep 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is 20/20 Biolabs Inc's price-to-sales ratio?
20/20 Biolabs Inc (AIDX) trades at 3.6x sales, its market capitalization divided by revenue of $2.0M revenue, FY2025. The market capitalization is $7.4M as of Sep 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does 20/20 Biolabs Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, 20/20 Biolabs Inc (AIDX) held $1.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $1.9M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is 20/20 Biolabs Inc's debt-to-equity ratio negative or not reported?
20/20 Biolabs Inc (AIDX) has negative shareholder equity of -$19K as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is 20/20 Biolabs Inc's Altman Z-Score?
20/20 Biolabs Inc (AIDX) has an Altman Z-Score of -12.64, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is 20/20 Biolabs Inc's Piotroski F-Score?
20/20 Biolabs Inc (AIDX) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are 20/20 Biolabs Inc's earnings high quality?
20/20 Biolabs Inc (AIDX) reported a net loss of $3.7M while operations used $1.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can 20/20 Biolabs Inc cover its interest payments?
20/20 Biolabs Inc (AIDX) reported an operating loss of $3.3M against $156K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is 20/20 Biolabs Inc?
20/20 Biolabs Inc (AIDX) scores 29 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.